| Ytd | -8.51% | |
| 1y | -49.43% |
| Open | 4.42 | Prev Close | 4.37 | Low | 3.19 | High | 4.64 | Mkt Cap | 19.19M |
| Vol | 637.62K | Avg Vol | 65.06K | EPS | -7.90 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-17 | 50-d Avg | 4.85 | 200-d Avg | 5.75 | 1yr Est | 0.00 |
Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical
Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combinati
Major M&A deals this week include: LVMH agrees to sell Marc Jacobs to WHP Global, 365 Markets bu
HC Wainwright & Co. analyst Joseph Pantginis downgrades Neuphoria Therapeutics (NASDAQ:NEUP)
Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.09) per share which beat the a